
Tumor-associated macrophages (TAMs) are a key immune population that influences the immunosuppressive microenvironment and drives the malignant progression of esophageal squamous cell carcinoma (ESCC). This review summarizes the mechanisms by which TAMs promote ESCC progression through facilitating tumor proliferation, angiogenesis, metastasis, and therapeutic resistance. TAM-directed therapeutic strategies have progressed from early methods of depletion and reprogramming to emerging directions such as phenotypic remodeling, phagocytic checkpoint intervention, and precursor cell targeting. However, the compensatory nature and plasticity of the tumor microenvironment limit the efficacy of monotherapy. The combination of TAM-targeted therapies with immune checkpoint inhibitors, chemotherapy, or anti-angiogenic agents shows potential for reversing immunosuppression and overcoming clinical resistance. Future efforts should focus on elucidating TAM heterogeneity using single-cell and spatial multi-omics technologies and advancing the clinical use of biomarkers and smart drug delivery systems, thereby providing novel pathways for optimizing therapeutic strategies for ESCC.
ObjectiveTo construct a nomogram for predicting the overall survival rate of patients with gallbladder cancer with positive regional lymph nodes (LNs). MethodsData of 1413 patients diagnosed with gallbladder cancer with regional LN metastases from 2000 to 2022 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute in the United States. The patients were randomly divided into a training set and a validation set at a ratio of 7:3. The Cox proportional hazards regression model was used to explore the independent risk factors affecting the survival of patients and construct a nomogram. The receiver operating characteristic (ROC) curve, calibration curve, and clinical decision curve were drawn to evaluate the predictive ability of the model. ResultsMultivariate Cox analysis showed that age, T stage, M stage, grade, surgery, radiotherapy, and chemotherapy were independent risk factors affecting the overall survival rate of patients with gallbladder cancer with positive regional LNs (P<0.05). These factors were all included in the nomogram to construct the prediction model. The areas under the ROC curves for 6 months, 1 year, and 3 years in the training set were respectively 0.849, 0.825 and 0.821; those in the validation set were respectively 0.826, 0.828 and 0.795. The calibration curves showed good calibration in both the training set and the validation set. The clinical decision curve showed high clinical application value. ConclusionThe constructed nomogram model has good predictive ability and can help clinicians predict the overall survival of patients with gallbladder cancer with positive regional LNs, facilitating individualized treatment.
NUT carcinoma (NUT cancer), characterized by NUT gene rearrangement, is a rare but highly aggressive malignancy with an extremely poor prognosis, for which effective treatment options are currently lacking. Patient-derived organoid technology can maintain the molecular pathological characteristics of tumors over extended periods in vitro, providing an irreplaceable experimental platform for elucidating the pathogenesis of NUT carcinoma, screening targeted drugs, predicting treatment responses, and facilitating personalized precision medicine. To standardize the comprehensive application of NUT carcinoma organoid technology (from basic research to clinical translation), the International Society of Organoid Research has collaborated with a multidisciplinary team of domestic experts to formulate a consensus based on clinical requirements, current research progress, and clinical practice. This consensus systematically defines the principles for the establishment and quality control of organoids and further clarifies specific strategies for their application in basic research and clinical settings. This consensus aims to improve the overall quality of diagnosis and treatment and enhance patient outcomes by constructing a comprehensive standardized system.
ObjectiveTo explore the regulatory mechanism of methyltransferase like protein 3 (METTL3)–mediated m6A methylation in promoting pri-microRNA 150 (miR-150) maturation in esophageal squamous cell carcinoma (ESCC). MethodsQuantitative real-time PCR and Western blot analysis were used to detect the expression of METTL3, pri-miR-150, miR-150, and MYB in ESCC cell lines, and lentiviral transfection and cell proliferation assays were applied to explore the role of METTL3 in ESCC cell proliferation. RNA immunoprecipitation and co-immunoprecipitation assays were used to confirm that METTL3 binds DGCR8 and regulates pri-miR-150 processing and maturation in an m6A methylation–dependent manner. Luciferase reporter assays were utilized to map the direct binding sites between miR-150 and MYB. Colony formation and CCK-8 assays confirmed that miR-150 functions in METTL3-induced ESCC cell proliferation. ResultsMETTL3 expression was substantially upregulated in ESCC tissues and corresponding cell lines. ESCC cell proliferation was suppressed by METTL3 knockdown or enhanced by METTL3 overexpression. METTL3 mediates miR-150 processing and maturation via DGCR8, and miR-150 rescues METTL3-induced ESCC cell proliferation by targeting the MYB transcription factor. ConclusionThis study demonstrates that METTL3 promotes pri-miR-150 processing and maturation in an m6A methylation–dependent manner by interacting with DGCR8, thereby enhancing ESCC cell proliferation and providing novel insights into ESCC diagnosis and treatment.
ObjectiveTo investigate the mechanism by which crocin (CRO) induces immunogenic cell death (ICD) in nasopharyngeal carcinoma (NPC) cells via the CASP8/TNFAIP3 axis. MethodsCCK-8, Transwell, and TUNEL assays were used to detect the effects of CRO on CNE-1 viability, invasion, and apoptosis. Immunofluorescence staining and ELISA were performed to examine the expression levels of ICD markers (CRT, HMGB1, ATP, HSP70, and HSP90). Transwell co-culture combined with qRT-PCR was utilized to detect the expression of the DC surface markers CD80 and CD1a. Western blot analysis and Co-IP were employed to analyze CASP8–TNFAIP3 interaction. Functional rescue experiments applied siRNA knockdown and plasmid overexpression. ResultsCRO dose-dependently inhibited CNE-1 viability and invasion; induced apoptosis; and promoted CRT exposure and HMGB1, ATP, HSP70, and HSP90 secretion (all P<0.05). DC-CNE-1 co-culture experiments showed that CRO reversed the inhibition of DC maturation by CNE-1, upregulating CD80 and CD1a expression (all P<0.05). CRO upregulated the expression of CASP8 and TNFAIP3 in CNE-1 cells; CASP8 knockdown reversed the anti-tumor effects of CRO and suppressed ICD and DC maturation; and TNFAIP3 overexpression reversed the phenotypic changes caused by CASP8 knockdown, including increased cell viability and invasion and decreased apoptosis and ICD marker levels (all P<0.05). Co-IP experiments confirmed CASP8–TNFAIP3 interactions. ConclusionCRO induces ICD in NPC cells via CASP8/TNFAIP3 activation, promoting DC maturation and providing a novel target for NPC immunotherapy.